Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity

Caroline Benedicte Kjærulff Mathiesen

    Research output: Contribution to conference without a publisher/journalPosterCommunication

    Original languageEnglish
    Publication date30 Jan 2018
    Publication statusPublished - 30 Jan 2018
    EventKeystone Symposia: Emerging Technologies in Vaccine Discovery and Development - Banff, Canada
    Duration: 28 Jan 20182 Feb 2018

    Conference

    ConferenceKeystone Symposia
    LocationBanff, Canada
    Period28/01/1802/02/18

    Cite this